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Abstract
Background We investigated the anti-inﬂammatory and
immunomodulatory effect of simvastatin on articular car-
tilage via the inhibition of matrix metalloproteinase-3
(MMP-3), a matrix-degrading enzyme, in a mechanically
induced experimental osteoarthritis (OA) animal model.
Materials and methods Twenty-seven albino Wistar rats
were divided in three groups of equal number. Unphysio-
logic loading of articular cartilage was simulated by tran-
secting anterior cruciate ligaments of the right knees of 18
rats consisting of groups 1 and 2. Nine animals in group 2
received orally administered simvastatin 20 mg/kg per day
by gavage for 8 weeks. Animals in group 3 were sham
operated. All animals were sacriﬁced at postoperative
8 weeks. Effects of simvastatin on disease progression was
evaluated by documenting OA changes in cartilage speci-
mens using Osteoarthritis Research Society International
(OARSI) OA cartilage histopathology assessment system
scores combined with the percentage of MMP-3 expression
in chondrocytes.
Results Simvastatin treatment signiﬁcantly down-regu-
lated the percentage of MMP-3 expression in chondrocytes
as assessed by immunohistochemistry methods. Suppres-
sion of this matrix-degrading enzyme by simvastatin also
reduced OARSI scores, suggesting the potential for statins
against OA progression.
Conclusions Following knee trauma, OA initiates at the
molecular level in a short period of time. Irreversible
structural changes in cartilage that require demanding
treatment strategies led us to focus on effective measures to
prevent OA. Statins have immunomodulatory and anti-
inﬂammatory properties independent from their serum-
cholesterol-lowering effects. One of these widely used
drugs, simvastatin, showed beneﬁcial effects on OA pro-
gression and extent by reducing cartilage degradation in
our experimental setting. If these results are conﬁrmed by
human trials, simvastatin might be considered by ortho-
pedic surgeons as a disease-modifying drug during the
early inﬂammatory phase of posttraumatic OA.
Keywords Simvastatin  Anterior cruciate ligament
transection  Knee osteoarthritis  Matrix
metalloproteinase-3
Introduction
Osteoarthritis (OA), characterized by progressive degra-
dation of cartilage, is the most common joint disease for
middle-aged and older people. In advanced stages of the
disease, limb dysfunction due to joint pain, deformity,
contracture, and muscle atrophy is a handicap in daily
living. The high frequency and chronicity of OA makes it a
substantial economic burden for patients and health care
systems. Thus we focused our study on effective preventive
measures. Currently, there is no disease-modifying treat-
ment for OA; available medical treatment for early OA is
based on symptomatic relief.
Although the pathophysiology of joint degeneration
remains poorly understood, increase in mechanical stress
and changes in biochemical factors within the affected joint
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is a complex, multifactorial process involving cartilage
catabolism and anabolism, as well as changes in other
tissues in the joints, such as the synovium, subchondral
bone, and tendons. Chondrocytes regulate cartilage
metabolism. Homeostasis of extracellular matrix is driven
mainly by enzymes secreted from these chondrocytes. As a
consequence of mechanical and biochemical events,
imbalance between synthesis and degradation of articular
cartilage matrix results in clinical OA. Advanced molecu-
lar studies emphasize that OA is not only a degenerative
disease, there is also an ongoing inﬂammatory process in
its pathophysiology [1–5]. Matrix metalloproteinases
(MMPs) and proinﬂammatory cytokines such as interleu-
kin-1 (IL-1), IL-6, and tumor necrosis factor alpha (TNF-a)
play an important role in this inﬂammatory process [6–8].
Several studies have provided evidence for a signiﬁcant
role of MMPs, particularly MMP-3, produced by chon-
drocytes in the development of cartilage degradation
[9–11]. MMPs, a gene family of zinc-dependant proteases,
are secreted from various cells, including chondrocytes,
synovial-lining cells, neutrophils, and macrophages. In
early studies, elevated levels of MMPs were found in
osteoarthritic knee and joint cartilage of humans undergo-
ing total joint replacement [12]. MMPs released by chon-
drocytes can be enhanced in conditions of mechanical or
chemical stresses, destroying nearly all components of the
cartilage matrix. Among the mediators of tissue injury, IL-
1 and TNF-a are actively involved in the progression of
cartilage damage and can stimulate MMP secretion from
chondrocytes and synovial tissues [13–15].
Statins are competitive inhibitors of hydroxymethyl-
glutaryl (HMG)-CoA reductase and are used worldwide as
the most effective drug to reduce serum cholesterol levels
by inhibiting the cholesterol biosynthesis pathway. HMG-
CoA reductase catalyzes the conversion of HMG-CoA to
mevalonate, a rate-limiting step in cholesterol biosynthesis.
Statins have been shown to have anti-inﬂammatory effects
that are unrelated to their lipid-lowering abilities [16, 17].
Based on the current literature, we aimed to investigate the
effects of statins in an experimental model of OA by
evaluating the percentage of MMP-3 expression in chon-
drocytes and OARSI OA cartilage histopathology scores.
Marterials and methods
All procedures were in compliance with the Principles of
Laboratory Animal Care (NIH publication No. 85–23,
revised 1985) and Turkish Law 6343/2 Veterinary Medi-
cine Deontology Regulation 6.7.26. The study was in
compliance with Gazi University Ethical Council regula-
tions, and the protocol was approved by Gazi University
Experimental Animals Ethical Council on 27 December
2007 by decision code B.30.2.GU ¨N.0.EU.00.00/113-
21239. The study was carried out in the Gazi University
Experimental Animal Research Laboratory and was sup-
ported by Gazi University Department of Scientiﬁc
Investigation Grant No: 01/2008-18.
Animals and surgical procedure
Twenty-seven male albino Wistar rats weighing approxi-
mately 300 g each were obtained from Gazi University
Experimental Animal Research Laboratory and were ran-
domly divided into three groups of equal numbers. All
surgical procedures were accomplished after intramuscular
administration of 40 mg/kg ketamine hydrochloride
(Ketalar, Pﬁzer Inc, USA) and 5 mg/kg xylazine hydro-
chloride. After being shaved and disinfected, right knees of
animals in group 1 and group 2 underwent anterior cruciate
ligament transection (ACLT) via a medial parapatellar
arthrotomy to simulate knee instability. After surgery, the
joint surface was washed with sterile saline solution, and
both capsule and skin were sutured using Vicryl 4-0
(Ethicon, Edinburgh, UK) absorbable suture. Animals in
group 1 were left untreated, whereas each animal in group
2 was treated with orally administered simvastatin (Merck
Sharp & Dohme, Middlesex, UK) 20/mg per kilogram per
day by gavage for 8 weeks starting from the ﬁrst day of
surgery. Animals in group 3 were sham operated with an
arthrotomy only using the same approach. All animals were
housed in different cages according to their groups, were
allowed unlimited activity, and were sacriﬁced 8 weeks
after the operation using an intravenous overdose of
anesthesia. Twenty-seven knee joints in all groups were
subsequently divided into femur (F) and tibia (T) sub-
groups. After disarticulation of the right knee joint, both
femur and tibia were dissected from muscle, and cartilage
was harvested from both medial and lateral tibial plateaus
and femoral condyles.
Tissue preparation, immunohistochemistry for MMP-3,
and histopathology
Excisional biopsy specimens of proximal tibia and distal
femur were ﬁxed in 10% formalin for 1 week and then
processed in 10% formic acid solution for decalciﬁcation.
Formic acid solution was renewed in every 24 h, and the
consistency of the bone was checked every day. The bone
specimens could be cut at 72 h. Proximal tibia specimens
were cut into two pieces in the sagittal plane, proximal
femoral specimens were cut into two pieces in the coronal
plane, and specimens were embedded in parafﬁn blocks to
be sectioned on their cut surfaces. Three-micron-thick
146 J Orthopaed Traumatol (2011) 12:145–151
123sections were cut on two slides: one to be stained by
hematoxylin and eosin and the other by MMP-3 antibody.
Immunohistochemical assays were performed on formalin-
ﬁxed, parafﬁn-embedded sections. After deparafﬁnization,
sections were rehydrated with distilled water. Endogen
peroxidase activity was blocked by 3% hydrogen peroxide
for 10 min and the specimens were then washed in distilled
water. Antigen retrieval was performed in citrate buffer pH
6.0 in a microwave oven at high temperature for 20 min for
MMP-3. After standing for 20 min at room temperature,
slides were washed in phosphate-buffered saline (PBS) pH
7.6 for 5 min. After protein blockage (Lab Vision Ultra V
block, Fremont, CA, USA) for 10 min, tissue sections were
incubated in primary antibodies against MMP-3 dilution
1/100 (Abcam, Cambridge, CB4, 0FW, UK) for 1 h at
room temperature. After washing by PBS for 5 min, tissue
sections were incubated in biotinylated secondary anti-
bodies (Lab vision Fremont, CA, USA) for 20 min and
then washed with PBS for 5 min. Slides were incubated in
streptavidin/peroxidase complex (Lab vision Fremont, CA,
USA) for 20 min and washed by PBS for 5 min. Sections
were developed with the 3,3’ diaminobenzidine (DAB) as
the chromogen and counterstained with hematoxylin.
Sections were incubated overnight in primary antibodies
against MMP-3 at 4C. Placenta sections were used as
positive controls for MMP-3.
The slides were screened by one pathologist. Positive
staining was determined as cytoplasmic staining in chon-
drocytes. Total number of chondrocytes and positive-
staining chondrocytes were counted in the femur and tibia,
respectively, in three or more sections on 3–6 high-power
ﬁelds (9400) according to the size of articular sections,
and mean count of these sections was used to determine a
proportion of cells expressing MMP-3. The pathologist was
masked to the experimental procedures.
Histopathological scores
Histopathological assessment was made using the OARSI
cartilage OA histopathology assessment system by the
same pathologist. This system is based on six grades and
four stages, reﬂecting the severity and extent of OA over
the joint surface. Grade is deﬁned as OA depth progression
into cartilage and is an index of severity or biologic pro-
gression of the osteoarthritic process. Grade is assessed by
noting the most advanced grade present within cartilage,
irrespective of its horizontal extent (grades 1–4: articular
cartilage changes only; grades 5–6: cartilage and sub-
chondral bone). Stage is deﬁned as the horizontal extent of
cartilage involvement irrespective of underlying grade.
Score is deﬁned as OA grade and OA stage (grade 9
stage). Therefore, scores represents a combined assessment
of OA severity and extent [18, 19].
Statistical analysis
Statistical comparisons were generated using Statistical
Package for Social Sciences-11 for Windows program
(SPSS, Chicago, IL, USA). All data are expressed as
means ± standard deviation (SD). Histopathology and
immunohistochemistry data were analyzed using a non-
parametric Mann–Whitney U test. P values \0.05 were
considered statistically signiﬁcant.
Results
Group 1 (ACLT) had a statistically signiﬁcant high per-
centage of MMP-3 expression in chondrocytes compared
with group 2 (ACLT ? simvastatin), and simvastatin
clearly suppressed MMP-3 expression in chondrocytes
(P = 0.001; Fig. 1; Table 1). Group 3 (control) had lower
MMP-3 staining compared with groups 1 and 2, whereas
there was no statistically signiﬁcant difference between the
percentage of MMP-3 expression in chondrocytes between
groups 2 and 3 (P = 0.429; Fig. 2a, b, c; Table 1).
Group 2 had a signiﬁcantly higher OARSI cartilage OA
histopathology assessment score than that of group 3
(P\0.001), showing the ongoing osteoarthritic process,
whereas scores in group 2 were lower compared with group
1, indicating the decrease in the extent and severity of OA
(P = 0.004; Fig. 3; Table 1).
Despite group 1 (ACLT) having matrix discontinuity at
the superﬁcial zone, vertical and branched ﬁssures into the
mid zone, disorganization, and loss of collagen content,
Fig. 1 Distribution of chondrocyte matrix metalloproteinase-3
(MMP-3) staining of femur and tibia articular cartilage in three
groups
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123group 2 (ACLT ? simvastatin) had only superﬁcial ﬁbril-
lation and did not show disorganization and loss of colla-
gen content. Group 3 (control knees) had an intact surface
and normal matrix architecture (Fig. 4a, b, c).
Discussion
In this study, using a model of mechanically induced knee
OA in rats, we demonstrated that simvastatin, a HMG-CoA
reductase inhibitor, decreased the extent and severity of
OA by reducing MMP-3 expression in articular cartilage.
Most clinically prominent knee OA has a neglected history
of trauma. Malalignment and instability, resulting in
alteration of loading of the articular cartilage, initiates
complicated biochemical pathways, leading to matrix
degradation. In particular, repetitive shear and tangential
traction forces on the surface of the cartilage activates
TNF-a, IL-1, and MMP-mediated catabolic pathways.
Therefore, orthopedic surgeons must be aware of the
inﬂammatory phase and its outcomes, even after a minor
trauma. In surgically induced models, radiographic, mor-
phologic, and biochemical changes have been character-
ized in different animal models using dogs, rabbits, and rats
[20–22]. We created joint instability by transecting the
anterior cruciate ligament in a rat model and found that
increasing mechanical stress and altering loading on the
articular cartilage is characterized by progressive and
gradual changes in the histology of articular cartilage. We
believe that this model can mimic the pathogenesis of
human OA in terms of cartilage degradation after similar
traumas. This rat OA model with ACLT offered the
Fig. 2 a Micrographs from group 1 (anterior cruciate ligament
transection) distal femoral articular cartilage chondrocytes showing a
high percentage of matrix metalloproteinase-3 (MMP-3) staining
(MMP-3, immunoperoxidase 920). b Micrographs from group 2
(anterior cruciate ligament transection ? simvastatin) showing low
percentage of MMP-3 staining (MMP-3, immunoperoxidase 940).
c Micrographs from group 3 (control knees) showing no MMP-3
staining (MMP-3, immunoperoxidase 940)
Table 1 Articular cartilage
matrix metalloproteinase-3
(MMP-3) expression and
Osteoarthritis Research Society
International (OARSI)
histopathology scores in all
groups
Group 1 Group 2 Group 3
MMP-3 expression (%) 42.5 ± 21.0 (5–80) 14.4 ± 19.8 (0–50) 3.6 ± 4.1 (0–10)
P = 0.001 P = 0.429
OARSI histopathology
scores
9.4 ± 3.9 (4–16) 5.1 ± 3.6 (1–9) –
P = 0.004 P\0.001
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123advantages of relatively small size, low cost, and rapid
progression of cartilage degeneration in studying and
evaluating the effects of simvastatin on articular cartilage.
Novel experimental studies have demonstrated that OA is
not only a degenerative disease but also consists of an
ongoing inﬂammatory process with anabolism and catab-
olism [1–5]. Regarding this important data, our mechani-
cally induced OA model demonstrated cartilage
degradation in a short period of time as a result of the
ongoing inﬂammatory process.
During the inﬂammatory process although many pro-
teinases belonging to all classes are expressed in joint tis-
sues with OA, among them, MMPs are known to have a
key role in joint destruction. According to these ﬁndings,
we believe that blockade of this enzyme may be essential
for preventing the disease. Statins, HMG-CoA (3-hydroxy-
3-methylglutaryl-coenzyme A) reductase inhibitors, also
have a proven role as an immunomodulatory and anti-
inﬂammatory agent independent from their plasma-cho-
lesterol-lowering effects [17]. These anti-inﬂammatory
effects of statins were ﬁrst demonstrated in coronary artery
disease, in which statin treatment inhibited arterial-wall
inﬂammation, stabilized atherosclerotic plaques, and
reduced cardiovascular morbidity and mortality rates.
Studies have conﬁrmed that statins have a broad range of
effects on cells and tissues involved in the inﬂammation
process. Statins inhibit the production of IL-1b from human
peripheral blood mononuclear cells, MMP 1-3-9 from
Fig. 4 a Micrographs from group 1 (ACLT) showing matrix
discontinuity at the superﬁcial zone, matrix vertical and branched
ﬁssures into mid zone [hematoxylin and eosin (H&E) 910].
b Micrographs from group 2 (ACLT ? simvastatin) showing only
superﬁcial ﬁbrillation (H&E 920). c Micrographs from group 3
(control knees) showing a intact surface and normal matrix architec-
ture (H&E 920)
Fig. 3 Distribution of Osteoarthritis Research Society International
(OARSI) osteoarthritis (OA) pathology assessment scores of femur
and tibia in all groups
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123rabbit macrophages, MMP-3 from IL-1b-stimulated human
chondrocytes, and monocyte chemoattractant protein-
1(MCP-1) from human peripheral monocytes, which pre-
vents circulating monocytes from migrating to the arterial
wall [23, 24].
Although statins have been reported to decrease the
production of MMP-3 from IL-1b-stimulated chondrocytes
and MMP-1,-3,-9 from macrophages, the mechanism of
their inhibitory effects on MMP production in various cells
is still controversial. Some studies suggest that statins
modulate chondrocyte metabolism by reducing prenylation
of key signaling molecules that control expression of col-
lagen-degrading enzymes [25]. Among statin derivates,
simvastatin had the advantage of lipophilic properties and
the ability to passively diffuse into cells at a dose-dependent
rate.Themethodofstatinadministrationisalsoanimportant
issue, as various methods such as intraperitoneal and intra-
articular administration have been used to investigate its
suppressing effect on inﬂammation in arthritis models [26].
Oral administration—a simple, effective, and more physi-
ologic procedure—avoided the side effects of parenteral use
and was favored in this study. Although the effective con-
centrations used were higher than human therapeutic values
for hypercholesterolemia (1.5 mg/kg per day), no reverse
effects of simvastatin on cell viability was observed.
In light of these ﬁndings, the main goal must be to
suppress the ongoing inﬂammatory process by inhibiting
the matrix-degrading enzyme activity of MMPs. We
hypothesize that simvastatin may decrease cartilage deg-
radation and AO progression by inhibiting MMP-3
expression in chondrocytes. Assessed by immunohisto-
chemical methods, MMP-3 staining in chondrocytes were
found to be signiﬁcantly decreased. Parallel to this ﬁnding,
using histopathological methods, OA extent and severity in
the simvastatin-treated group decreased compared with in
the untreated group. These results support our hypothesis.
Depending on the previous ﬁndings, down-regulation of
MMP-3 by simvastatin itself may be sufﬁcient to deceler-
ate the degradation process in OA.
To the best of our knowledge, this is the ﬁrst study to
investigate the effects of orally administered simvastatin on
OA cartilage by evaluating chondrocyte MMP-3 expres-
sion and articular cartilage histopathologic OA assessment
score in a mechanically induced OA model. Simvastatin
may be used as a disease-modifying agent by suppressing
the inﬂammatory phase and has a promising role in OA
prevention for humans. Future clinical and prospective
studies are needed to investigate the therapeutic importance
of this agent by inhibiting MMP-3 expression in humans,
especially in the early phase of posttraumatic knee OA.
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